Neostem (NBS -15.3%) trades sharply lower on the session. Perhaps weighing on the shares is a...

Neostem (NBS -15.3%) trades sharply lower on the session. Perhaps weighing on the shares is a paper by Stanford's Dr. Irving Weissman and others which questions the existence of pluripotent VSELs in mice.
Comments (23)
  • gsterling
    , contributor
    Comments (1334) | Send Message
    I've stayed awake many a night wondering the same thing.
    24 Jul 2013, 01:32 PM Reply Like
    , contributor
    Comments (72) | Send Message
    Never heard of the guy but he's lowering the value of my portfolio and pissing me off....
    24 Jul 2013, 01:43 PM Reply Like
  • uckinallstar
    , contributor
    Comments (92) | Send Message
    There are many other studies showing the ability to manipulate stem cells and they do exist in humans.
    24 Jul 2013, 01:57 PM Reply Like
  • Oliver L.
    , contributor
    Comments (135) | Send Message
    The "article" states that the paper questions the existence of these cells in mice, not humans.
    24 Jul 2013, 02:01 PM Reply Like
  • GDW1
    , contributor
    Comments (74) | Send Message
    I'll break the news to my mice very gently.
    24 Jul 2013, 02:07 PM Reply Like
  • Scrying Biotech
    , contributor
    Comments (2741) | Send Message
    GDW ~ I got out of bed too fast days like today are made a little easier when someone makes me laugh. Thank you!
    24 Jul 2013, 02:22 PM Reply Like
  • smokess
    , contributor
    Comments (43) | Send Message
    VSEL is only a part of Neostem's arsenal. This news has nothing to do with AMR-001, their Pase II study, nor does it take into account their contract manufacturing business, currently generating $14m+ annual revenue. And, at $7 per share, it's still way above the reverse split price of $5.50 just a week ago. I'm still way long NBS.
    24 Jul 2013, 02:11 PM Reply Like
  • pagreen1966
    , contributor
    Comments (661) | Send Message
    I'm adding to my position.
    24 Jul 2013, 02:19 PM Reply Like
  • brewbob47
    , contributor
    Comments (29) | Send Message
    I find the article's premise very weak. My thought was that a lot of people took profits, the gaps are closed and weak hands are being shaken out. Nothing has changed on the fundamentals. Fully agree, smokess.
    24 Jul 2013, 03:00 PM Reply Like
  • Justreward
    , contributor
    Comments (113) | Send Message
    I added a little as well @ 6.90 and looking to add more in the coming days on a re-test of today's intra-day low of $6.71 should it show support.
    24 Jul 2013, 03:23 PM Reply Like
  • kblair
    , contributor
    Comments (2) | Send Message
    He's from Stanford. Extrapolate to a liberal bias, animosity toward anything supported by pro-life groups or anything supplanting and highlighting the failure of embryonic stem cells. Expect more of the same from intelligentsia. NBS will succeed or fail on its own merits.
    24 Jul 2013, 02:26 PM Reply Like
  • dugafish
    , contributor
    Comments (22) | Send Message
    ah-ahem-you may want to consider that Dr. Weiss, author of the scientific article is on the BOD of STEM and considered one of its founders. Read and learn, huh?
    24 Jul 2013, 09:24 PM Reply Like
  • travis543
    , contributor
    Comments (22) | Send Message
    This has absolutely nothing to do with STML
    24 Jul 2013, 03:44 PM Reply Like
  • dugafish
    , contributor
    Comments (22) | Send Message
    why are you wasting your fine intellect on this SA massage board defending STML? Get back on twitter. It was sold off because its overbought and slightly ahead of itself. Just keep buying the dips!
    25 Jul 2013, 07:10 AM Reply Like
  • AltaClip
    , contributor
    Comments (49) | Send Message
    The drop has more to do with the markets today and profit taking from it's incredible run +30% the last week than any article. Maybe some short positions coming in too but that's to be expected with a big run.
    24 Jul 2013, 08:05 PM Reply Like
    , contributor
    Comments (3) | Send Message
    VSELs have been shown to operate in mice according to other studies -


    The adult bone marrow (BM) harbors Sca-1+/Lin-/CD45- pluripotent very small embryonic-like stem cells (VSELs), which can differentiate in vitro into several lineages, including cardiac and vascular lineages. Since mobilization of stem/progenitors from the BM is a prerequisite for their participation in organ repair, we investigated whether VSELs are mobilized into the peripheral blood (PB) after acute myocardial infarction (MI). Wild-type mice (C57BL/6 strain, 6- or 15-wk-old) underwent a 30-min coronary occlusion followed by reperfusion (groups III-V, VIII-X, n=6-12/group) or a 1-hour open-chest state (sham controls, groups II and VII, n=8-12/group); mice were sacrificed 24 h, 48 h, or 7 days later and PB samples were harvested. Controls (groups I and VI, n=6/group) were sacrificed without any intervention. By flow cytometry, VSELs were barely detectable in PB under baseline conditions but their levels increased significantly at 48 h after MI, both in younger (6-wk-old) and older (15-wk-old) mice (3.33+/-0.37 and 7.10+/-0.89 cells/microl of blood, respectively). At 48 h after MI, qRT-PCR analysis revealed significantly increased levels of mRNA of markers of pluripotency (Oct-4, Nanog, Rex-1, Rif1, and Dppa1) in PB cells of 6-wk-old (but not 15-wk-old) infarcted mice compared with either controls or sham controls. Confocal microscopy and ImageStream analysis confirmed that mobilized VSELs expressed Oct-4 protein, while Sca-1+/Lin-/CD45+ hematopoietic stem cells did not. This is the first demonstration that Oct-4+ pluripotent stem cells (VSELs) are mobilized from the BM into the PB after acute MI. This phenomenon may have pathophysiological and therapeutic implications for repair of infarcted myocardium.
    24 Jul 2013, 08:29 PM Reply Like
    , contributor
    Comments (3) | Send Message
    Research supports NBS in a study by Zuba-Surma EK, Kucia M, Dawn B, Guo Y, Ratajczak MZ, and Bolli R of the Stem Cell Institute, University of Louisville, published in the Journal of molecular and cellular cardiology 44:5 2008 May pg 865-73. Stanford study reportedly had problems with methodology.
    25 Jul 2013, 08:39 AM Reply Like
    , contributor
    Comments (3) | Send Message
    Stanford is not the only lab doing work on VSELs. NeoStem VSEL interests are supported by other research, of which I cited previously a public abstract of results by Zuba-Surma EK, Kucia M, Dawn B, Guo Y, Ratajczak MZ, Bolli R of Stem Cell Institute, University of Louisville, from Journal of molecular and cellular cardiology 44:5 2008 May pg 865-. It may be found at the following site:
    25 Jul 2013, 08:40 AM Reply Like
  • mlefran
    , contributor
    Comments (12) | Send Message
    I'm staying in with a current profit and possibly selling some AAPL to add to my position. AAPL rumors are just that so far. NBS appears to be solid in several ways.
    24 Jul 2013, 08:35 PM Reply Like
  • iberia
    , contributor
    Comments (44) | Send Message
    Once more, bad news destroy more rapidly than good ones help to grow. So is the human nature.
    Huge fans of NBS should take advantage of the latest scoop to pick up some shares more.
    I think a public response/clarification from Neostem management should be appropriate in this connection.
    24 Jul 2013, 09:02 PM Reply Like
  • jersONEr
    , contributor
    Comments (20) | Send Message
    im worried that CEO gave no real defense response... showing no substantive denial at all.
    24 Jul 2013, 10:22 PM Reply Like
  • asms
    , contributor
    Comments (41) | Send Message
    I bought some shares today.
    24 Jul 2013, 10:41 PM Reply Like
  • getgl
    , contributor
    Comments (869) | Send Message
    If this was all Neostem had up their sleeve I'd be concerned but it is NOT. You have to see Neo as a more diverse company, which it is. That said, nobody made any guarantees that this specific area was a "done deal."
    25 Jul 2013, 03:27 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs